Home
NICE Guidance
Published Guidance

Daratumumab monotherapy for treating relapsed and refractory multiple myeloma

Technology appraisal guidance [TA510] Published: 14 March 2018

Guidance

This guidance has been updated and replaced by NICE technology appraisal guidance 783.